Rinvoq (upadacitinib) demonstrated superiority versus Humira (adalimumab) for primary endpoint in a head-to-head study in rheumatoid arthritis patients who have failed first TNF Inhibitor – AbbVie
AbbVie announced positive topline results from the Phase IIIb/IV head-to-head SELECT-SWITCH study evaluating the efficacy and safety of upadacitinib (Rinvoq) 15 mg, once daily, compared to adalimumab (Humira)… read more.
